Notifications
Back

Daewoong Therapeutics is a R&D based biopharmaceutical company that specialize in development of novel therapeutics and drug delivery solutions

We strive to improve the quality of life of humans and animals through patient-centered development of innovative new drugs.

  • 01

    Small Molecule Drugs

  • 02

    Proteolysis Targeting Chimera (PROTAC)

  • 03

    Microneedle Platform Technology

  • 04

    CDO Services for Supergenerics and 505(b)(2) Products

  • 05

    Drug Repurposing and Repositioning

  • 06

    Veterinary Health Care

Daewoong Therapeutics Corporation status


  • Founded in Feb 1st, 2019
  • 2022 Awardee for Company with Excellent Technology
  • Certified Company for Compensatory Job Creation
  • Major Shareholders: Daewoong Co., Ltd., CG Bio and Founders
  • 27 Dongtahcheomdansaneop 1-ro, Geumgand Penterium IX Tower #A-401, Hwaseong-si, Gyeonggi-do, South Korea

Corporate Location


  • 27 Dongtahcheomdansaneop 1-ro, Geumgand Penterium IX Tower #A-401, Hwaseong-si, Gyeonggi-do, South Korea
  • Headquarters, R&D Center

Business Areas


  • Proteolysis Targeting Chimera (PROTAC)
  • Microneedle Platform
  • CDO Services for Supergenerics/505(b)(2) and Dosage Development
  • Veterinary Medicine
  • Veterinary Medicine
  • Advanced Drug Delivery using Implants and Microspheres

Major Achievements


  • More than 25 patent applications
  • DWRX1004: Domestic Approval and Market Release in 22 1Q
  • DWRX5001: Funded Assignment by the Ministry of Trade, Industry and Energy (5 billion KRW/5yr
  • DWRX2013 for Aortic Stenosis: Funded Assignment by the Ministry of Trade, Industry and Energy (3 billion KRW/4yr)
  • DWRX2008 for Diabetic Retinopathy: Funded Assignment by the Ministry of Trade, Industry and Energy (2 billion KRW/2yr)

Dongtan HQ and R&D Center.

Core Values and Mission

Innovative mindset that confronts challenges for the future of global wellness

Open communication for mutually beneficial network with various stakeholders

Encouraging creativity and teamwork for autonomous workflow

Strong work ethic that guarantees integrity, dedication and professionalism

Introducing Daewoong Therapeutics's
 corporate growth roadmap.

2022

Quantum Jump

Mar.Released DWRX1004 tablets (Rabeprazole + Sodium bicarbonate)
(Distributors: Dong-A ST, Dong-Hwa, Ildong, Samjin, and Youngjin Pharm)
Apr.Funded project by the Korea Drug Development Foundation (KDDF), HN22C0450
Nov.DWRX1004 sales exceeded KRW 5 billion

2021

Build-up & Ideation

Mar.development and technology transfer of nanocarrier eyedrop formulation of new drug candidate
Apr.Final grantee selected by the Ministry of Commerce, Industry and Energy for the development of treatment for intractable aortic valve stenosis
MayExecution of collaborative research agreement for screening new small molecule drugs and PROTAC with Net Target
Aug.Technology transfer of microneedle technology to CG Bio
Sep.Final grantee of the 2022 Technical Accelerator Award funded by the RIGHT Fund

2020

Build-up & Ideation

Mar.Technology transfer of DWRX1004 and PCT application for microneedle technology
Apr.Corporate affiliated research institute certification
Nov.Venture company certification

2019

First day of our company

Feb.Established Daewoong Therapeutics Co., Ltd.
Mar.Microneedle platform patent application
Dec.Technology transfer of Supergeneric/505(b)(2)